GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InnoCan Pharma Corp (XCNQ:INNO) » Definitions » Debt-to-Asset

InnoCan Pharma (XCNQ:INNO) Debt-to-Asset : 0.01 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is InnoCan Pharma Debt-to-Asset?

InnoCan Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.03 Mil. InnoCan Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.02 Mil. InnoCan Pharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was C$9.31 Mil. InnoCan Pharma's debt to asset for the quarter that ended in Dec. 2023 was 0.00.


InnoCan Pharma Debt-to-Asset Historical Data

The historical data trend for InnoCan Pharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCan Pharma Debt-to-Asset Chart

InnoCan Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial 0.03 0.01 - 0.01 0.01

InnoCan Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 - - - 0.01

Competitive Comparison of InnoCan Pharma's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, InnoCan Pharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnoCan Pharma's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InnoCan Pharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where InnoCan Pharma's Debt-to-Asset falls into.



InnoCan Pharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

InnoCan Pharma's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

InnoCan Pharma's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InnoCan Pharma  (XCNQ:INNO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


InnoCan Pharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of InnoCan Pharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


InnoCan Pharma (XCNQ:INNO) Business Description

Traded in Other Exchanges
Address
1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals. Geographically, it derives a majority of its revenue from the United States.

InnoCan Pharma (XCNQ:INNO) Headlines

From GuruFocus

Innocap, Inc.'s Current Activities

By Marketwired Marketwired 05-24-2018

Innocap, Inc. Year End Message To Shareholders

By PRNewswire PRNewswire 12-14-2020

President of Innocap, Inc. is in Singapore

By GlobeNewswire GlobeNewswire 05-03-2018

President of Innocap, Inc. is in Singapore

By Marketwired Marketwired 05-03-2018